attributable to the Equity of the Company in Q2/2019 amounted to Bt176.1 million, a decrease of Bt66.2 million or 27.3%(y-o-y) and equivalent to earnings per share of Bt0.28. And in the first six months of the
43.6% compared to 43.7% in the same period of last year. And resulted in EBITDA of Bt1,109.0 million, increasing by Bt34.5 million or 3.2% (y-o-y), equivalent to EBITDA margin at 58.3% compared to 58.7
resulted in EBITDA was of Bt1,690.9 million, increasing by Bt77.2 million or 4.8% (y-o-y), equivalent to EBITDA margin at 59.5% compared to 59.4% of the same period of last year. 1.2.3 Finances Cost The
, 2021. The changes described as follows: Assets Items that has significant changes Balance by Quarter Change Q2–22 Q4–21 Q2-22 VS Q4-21 (MB) (MB) % Cash and cash equivalent 727.80 378.5 349.3 92.3 Other
Committee, the Bank of Thailand, had cut the policy rate twice, from 1.75% p.a. down to 1.50% p.a. in August, and cut again to 1.25% p.a. in early November. This is the lowest rate, almost equivalent to the
42.58 percent compared to the previous quarter, which was still better than the target. In this quarter, our impairment loss on loans and debt securities increased slightly from the prior quarter, but
regulations which will take effect in 2020, especially the Thai Financial Reporting Standards (TFRS9), and capital requirements, as well as other additional measures intended to mitigate the household debt
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
the target. In this quarter, our impairment loss on loans and debt securities increased slightly from the prior quarter. At the same time, our robust capital position was sufficient to cushion against